Comparative Pharmacology
Head-to-head clinical analysis: SEGLENTIS versus TEXACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SEGLENTIS versus TEXACORT.
SEGLENTIS vs TEXACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SEGLENTIS is a fixed-dose combination of the opioid oxycodone and the opioid antagonist naltrexone. Oxycodone acts as a mu-opioid receptor agonist, providing analgesia. Naltrexone is intended to reduce the abuse potential of oxycodone by blocking opioid receptors when the drug is tampered with (e.g., crushed or chewed), but is sequestered in the core of the tablet and not released when taken orally as directed.
TEXACORT (hydrocortisone) is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, immunosuppressive, and metabolic effects.
Subcutaneous injection: 300 mg (1.5 mL) once weekly. Administer in combination with oral capecitabine.
50 mg intravenously every 6 hours as a single agent or in combination with other antineoplastic agents.
None Documented
None Documented
The terminal elimination half-life of celecoxib is approximately 11 hours; for tramadol, it is about 6 hours, and for its active M1 metabolite, about 7 hours. Clinically, this supports twice-daily dosing for Seglentis (two tablets BID).
Terminal elimination half-life: 3-4 hours. In renal impairment, half-life may be prolonged up to 12 hours.
Seglentis (celecoxib and tramadol) is primarily excreted renally. Celecoxib is eliminated via hepatic metabolism (CYP2C9) with <3% excreted unchanged in urine; fecal excretion accounts for approximately 70% of an oral dose (as metabolites). Tramadol and its active metabolite (M1) are mainly excreted renally (about 90% of the dose, with 30% unchanged tramadol and 15% M1); the remainder is excreted fecally.
Renal: 80-90% as unchanged drug and inactive metabolites; biliary/fecal: 10-20%.
Category C
Category C
Corticosteroid
Corticosteroid